Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/12/2024 | $27.00 | Buy | Rodman & Renshaw |
| 3/5/2024 | $27.00 → $29.00 | Outperform | Oppenheimer |
| 3/5/2024 | $21.00 → $25.00 | Buy | H.C. Wainwright |
| 3/5/2024 | $20.00 → $22.00 | Buy | Needham |
| 2/6/2024 | $21.00 | Buy | UBS |
| 11/30/2022 | $6.50 → $11.00 | Hold → Buy | Jefferies |
| 8/10/2022 | $6.00 → $8.00 | Buy → Hold | Jefferies |
| 7/28/2022 | $15.50 → $12.00 | Buy | Craig Hallum |
DUBLIN, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20 at 7:30 a.m. GMT / 2:30 a.m. ET. A live webcast of the fireside chat, as well as an archived recording, will be available on Avadel's Investor Relations website, investors.avadel.com, for 90 days following the conference. About Avadel Pharmaceuticals plc Avadel Pharmaceuticals plc (NASDAQ:AVDL) is a biopharmaceutical company focused on transforming medicines to transform liv
-- Generated $50.0 million in net revenue from sales of LUMRYZ™ -- --2,300 patients on LUMRYZ as of September 30th, including 700 patients that initiated therapy in the quarter -- -- Received FDA approval for LUMRYZ for the treatment of cataplexy or EDS in patients 7 years and older with narcolepsy, granted ODE through October 16, 2031 -- -- LUMRYZ approval upheld by court in suit brought by Jazz regarding FDA's determination that LUMRYZ is clinically superior to twice-nightly oxybate products -- -- Progressed Phase 3 REVITALYZ™ study evaluating efficacy and safety of LUMRYZ in IH -- -- Management to host a conference call today at 8:30 a.m. ET -- DUBLIN, Ireland, Nov. 12
DUBLIN, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Tuesday, November 12, 2024, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2024. To access the conference call, investors are invited to dial (800) 579-2543 (U.S. and International) and reference the conference ID AVADEL. A live audio webcast of the call be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcas
Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024.
– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ – – Presentations highlight Avadel's continued commitment to address gaps in narcolepsy care –DUBLIN, May 22, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, announced today it will present 11 posters, and one oral presentation, supporting the use of LUMRYZ as a narcolepsy treatment option at SLEEP 2024, the 38th annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society on June 1-5, 2024, in Houston.
HC Wainwright & Co. analyst Oren Livnat maintains Avadel Pharmaceuticals (NASDAQ:AVDL) with a Buy and raises the price target from $25 to $27.
Rodman & Renshaw initiated coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $27.00
Oppenheimer reiterated coverage of Avadel Pharmaceuticals with a rating of Outperform and set a new price target of $29.00 from $27.00 previously
H.C. Wainwright reiterated coverage of Avadel Pharmaceuticals with a rating of Buy and set a new price target of $25.00 from $21.00 previously
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
SC 13G/A - AVADEL PHARMACEUTICALS PLC (0001012477) (Subject)
10-Q - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
8-K - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
8-K - AVADEL PHARMACEUTICALS PLC (0001012477) (Filer)
4 - AVADEL PHARMACEUTICALS PLC (0001012477) (Issuer)
DUBLIN, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Tuesday, November 12, 2024, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2024. To access the conference call, investors are invited to dial (800) 579-2543 (U.S. and International) and reference the conference ID AVADEL. A live audio webcast of the call be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcas
DUBLIN, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, August 8, 2024, to provide a corporate update and discuss the Company's financial results for the second quarter ended June 30, 2024. A live audio webcast of the call can be accessed by visiting the investor relations section of the Company's website, www.avadel.com. A replay of the webcast will be archived on Avadel's website for 90 days following the event. Participants may register for the conference call here and are advised
-- Generated $27.2 million in net revenue from sales of LUMRYZ™ -- -- Through March 31, greater than 2,800 patients enrolled in Avadel's RYZUP patient support services and more than 1,700 patients initiated therapy -- -- Pursuing expansion opportunities for LUMRYZ with sNDA in pediatric narcolepsy; on track to enroll first patient in a Phase 3 pivotal idiopathic hypersomnia trial in the second half of 2024 -- -- Management to host a conference call today at 8:30 a.m. ET -- DUBLIN, Ireland, May 08, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today provided a corporate update and anno
DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, effective at the open of US equity markets on Monday, July 1, 2024, according to a preliminary list of additions posted Friday, May 24, 2024. "We are proud to be included in the widely tracked Russell Indexes, which represents another important milestone for our company," said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. "We look forward to the enhanced visibilit
DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the appointment of Naseem Amin, M.D. to its board of directors, effective May 17, 2024. Dr. Amin, a highly successful executive who brings global industry and leadership experience to Avadel, currently serves as Chief Executive Officer of Orphalan SA. "On behalf of the entire Avadel team, we are excited to welcome Dr. Amin to our board of directors," said Geoffrey M. Glass, Avadel Chairman of the Board. "Dr. Amin's extensive experience in identifying, developing, and commercializing new medicines for d
DUBLIN, Ireland, March 14, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ:AVDL), a company focused on transforming medicines to transform lives, today announced the appointment of Brandi Robinson to the newly created position of Senior Vice President, Corporate Affairs. "We are pleased to welcome Brandi to the Avadel team as our Senior Vice President, Corporate Affairs as we continue to advance once-at-bedtime FT218 for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy," said Greg Divis, Chief Executive Officer of Avadel. "Brandi brings a wealth of corporate affairs experience in the biopharmaceutical industry, which will support the compa